Thu, October 3, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, October 2, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, October 1, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, September 30, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, September 17, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, September 16, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, September 11, 2024
[ 12:00 AM ] - WOPRAI
Fri, September 6, 2024
[ 12:00 AM ] - WOPRAI
Thu, September 5, 2024
[ 12:00 AM ] - WOPRAI
Tue, September 3, 2024
[ 12:00 AM ] - WOPRAI
Wed, August 28, 2024
[ 12:00 AM ] - WOPRAI
Tue, August 27, 2024
[ 12:00 AM ] - WOPRAI
Thu, August 22, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, August 19, 2024
Thu, August 15, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, August 14, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $60 on, Oct 3rd, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $60 on, Oct 3rd, 2024.
Raghuram has made no other calls on URGN in the last 4 months.
There are 3 other peers that have a rating on URGN. Out of the 3 peers that are also analyzing URGN, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Raghuram
- Kelsey Goodwin of "Guggenheim" Initiated at Strong Buy and Held Target at $40 on, Thursday, August 22nd, 2024
- Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $40 on, Friday, June 14th, 2024
- Matthew Kaplan of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $54 on, Friday, June 14th, 2024
Contributing Sources